NCT04854681Unknown1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TQB2928 Injection in Patients With Advanced Solid Tumors or Hematological Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 20
- 主要终点
- Dose Limiting Toxicities (DLTs)
研究概览
简要总结
TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα and enhances the phagocytosis of cancer cells by macrophages. In preclinical in vivo models, TQB2928 was active against a wide range of solid tumors and hematologic malignancies. This is the first-in-human phase 1 trial of TQB2928 in patients with advanced solid tumors and hematological malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
- •Histologically or cytologically confirmed, locally advanced unresectable or metastatic solid tumors, or hematological malignancies, or lymphoma.
- •Solid tumors or hematological malignancies that failed from standard therapy, or lymphoma patients who have had at least two regimens of systemic therapy failures, or who refused other systemic therapy.
- •At least 1 measurable lesion according to tumor-appropriate response criteria.
- •Must have adequate organ and bone marrow function.
- •Resolved acute effects of any prior therapy to baseline severity or Grade ≤1 per CTCAE v5.0 except for AEs not constituting a safety risk by investigator judgment.
- •Serum pregnancy test (for females of childbearing potential) negative within 7 days before enrollment.
- •Male and female patients of childbearing potential and at risk for pregnancy must agree to use two highly effective method(s) of contraception throughout the study and for at least 90 days (180 days if required by local regulation) after the last dose of assigned treatment.
- •Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.
排除标准
- •Patients with known symptomatic brain metastases requiring steroids.
- •Concurrent secondary malignancy.
- •Uncontrolled pleural effusion or pericardial effusion with clinical significance and requiring repeated drainage as assessed by the Investigators.
- •Prior treatment with monospecific or bispecific antibodies or fusion proteins targeting CD47 or signal regulatory protein alpha (SIRPα).
- •Therapeutic or experimental monoclonal antibodies within 28 days prior to enrollment.
- •Immunosuppressive regimens involving systemic corticosteroids (except <10 mg daily prednisone equivalent) within 14 days before the first dose of study treatment.
- •Prior allogeneic hematopoietic stem cell transplant.
- •Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment.
- •RBC transfusion dependence, defined as requiring more than 2 units of RBC transfusions during the 4-week period prior to screening. RBC transfusions are permitted during screening and prior to enrollment to meet the hemoglobin inclusion criteria.
- •Vaccination within 4 weeks prior to enrollment except for administration of inactivated vaccines (for example, inactivated influenza vaccines)
- •Active and clinically significant bacterial, fungal or viral infection including tuberculosis, hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
- •History of hemolytic anemia or Evans syndrome within 3 months.
- •Autoimmune hemolytic anemia (AIHA) assessed by Positive Direct Antiglobulin Test (DAT).
- •Autoimmune disorders (e.g., Crohn's Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus) and other diseases that compromise or impair the immune system.
- •Unstable or serious concurrent medical conditions in the previous 6 months.
- •Significant medical diseases or conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.
- •Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究组 & 干预措施
TQB2928 injection
Experimental
Dose Escalation: intravenous (IV) infusion of TQB2928 as monotherapy
干预措施: TQB2928 Injection (Drug)
结局指标
主要结局
Dose Limiting Toxicities (DLTs)
时间窗: During the first 28 days
DLTs will be assessed during the first 28 days of treatment for dose-escalation and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (28 days) of treatment.
Maximum tolerated dose (MTD)
时间窗: During the first 28 days
MTD is defined as the highest dosing schedule cohort level at which no more than 1 of 6 patients experience a Dose Limiting Toxicity (DLT).
次要结局
- Number of patients with adverse events (AEs) and serious adverse events (SAEs)(From the time of informed consent signed through 90 days after the last dose)
- Pharmacokinetics: Cmax(From the time of informed consent signed through 90 days after the last dose)
- Pharmacokinetics: Cmin(From the time of informed consent signed through 90 days after the last dose)
- Pharmacokinetics: Tmax(From the time of informed consent signed through 90 days after the last dose)
- Pharmacokinetics: AUC(From the time of informed consent signed through 90 days after the last dose)
- Pharmacokinetics: T1/2(From the time of informed consent signed through 90 days after the last dose)
- Percentage of ADA positive patients(From the time of informed consent signed through 90 days after the last dose)
- Objective Response Rate (ORR)(up to 2 years)
- Disease control rate (DCR)(up to 2 years)
- Duration of Response (DOR)(up to 2 years)
- Progression-free survival (PFS)(up to 2 years)
研究者
相似试验
招募中
1 期
Clinical Trial of the TQB2928 Injection in Patients With Advanced CancersAdvanced CancerNCT05192512Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.180
尚未招募
1 期
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung CancersAdvanced Non-small Cell Lung CancerNCT06585059Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.20
终止
1 期
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.Advanced Malignant NeoplasmNCT06297642Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3
终止
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I NeurofibromatosisNeurofibromatosis and Malignant Peripheral Nerve Sheath TumorsNCT05011019Chia Tai Tianqing Pharmaceutical Group Co., Ltd.22
已完成
1 期
To Evaluate Safety, Tolerability, Pharmacokinetics, And Food Effect Of Single Doses Of GSK945237 In Healthy SubjectsHealthy SubjectsInfections, BacterialNCT00517673GlaxoSmithKline68